Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Guanfacine
Drug ID BADD_D01046
Description Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension[L11274] but is now indicated as an extended release tablet for the treatment of ADHD.[L11277] Guanfacine was first described in the literature in 1974.[A189841] Guanfacine was granted FDA approval on 27 October 1986.[L11274]
Indications and Usage Guanfacine is indicated alone or as an adjunct with stimulants to treat ADHD.[L11277]
Marketing Status approved; investigational
ATC Code C02AC02
DrugBank ID DB01018
KEGG ID D08031
MeSH ID D016316
PubChem ID 3519
TTD Drug ID Not Available
NDC Product Code 0591-0444; 0591-0453; 27241-243; 42291-326; 60505-3928; 62135-728; 70436-040; 72162-2029; 16714-191; 16714-192; 42806-296; 60429-960; 70436-042; 71205-946; 0228-2855; 53746-711; 60505-3929; 60505-3930; 63629-1102; 63629-8203; 70518-1369; 71205-945; 63304-927; 65162-713; 70436-039; 70518-2771; 24658-730; 24979-198; 0228-2851; 63629-1105; 16714-190; 16714-193; 24979-538; 60429-961; 62135-727; 63629-8161; 70518-1371; 71205-947; 24979-199; 24979-536; 50268-374; 63304-926; 24658-731; 42806-048; 53746-713; 54092-515; 60429-962; 60429-963; 60505-3927; 63629-1103; 65162-711; 70436-041; 71335-9750; 72162-2030; 42291-327; 0228-2850; 0228-2853; 54092-517; 63187-302; 63304-924; 63304-925; 71205-944; 24979-534; 27241-242; 42291-325; 50090-5991; 54092-519; 63629-1104; 68094-065; 70518-0793; 0904-7140; 24979-533; 42291-324; 50090-6073; 50090-6493; 54092-513
UNII 30OMY4G3MK
Synonyms Guanfacine | Tenex | Guanfacine Hydrochloride | Hydrochloride, Guanfacine | Guanfacine Monohydrochloride | Monohydrochloride, Guanfacine | Lon798 | BS-100-141 | BS 100 141 | BS100141 | Estulic
Chemical Information
Molecular Formula C9H9Cl2N3O
CAS Registry Number 29110-47-2
SMILES C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Conjunctivitis11.01.06.012; 06.04.01.002--
Constipation07.02.02.0010.000554%
Crying08.01.03.005; 19.04.02.002; 17.02.05.013; 12.02.11.0010.000761%Not Available
Deafness04.02.01.0010.000173%Not Available
Decreased interest19.15.02.0040.000381%Not Available
Dehydration14.05.05.0010.000346%
Delusion19.10.01.0010.000173%
Depressed level of consciousness17.02.04.0020.000605%
Depressed mood19.15.02.0010.000640%Not Available
Depression19.15.01.0010.000640%
Dermatitis23.03.04.002--Not Available
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Disturbance in attention19.21.02.002; 17.03.03.0010.000554%
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.0030.002993%
Dizziness postural02.11.04.008; 24.06.02.008; 17.02.05.0040.000554%Not Available
Drug dependence19.07.06.011--Not Available
Drug ineffective08.06.01.0060.007542%Not Available
Dry mouth07.06.01.0020.000173%
Dysgeusia17.02.07.003; 07.14.03.0010.000259%
Dyspepsia07.01.02.001--
Dysphagia07.01.06.003--
Dyspnoea02.11.05.003; 22.02.01.004--
Emotional disorder19.04.02.0050.000882%Not Available
Enuresis20.02.02.003; 19.07.04.0010.001142%Not Available
Epilepsy17.12.03.0020.001211%Not Available
Epistaxis24.07.01.005; 22.04.03.0010.000173%
Eye disorder06.08.03.001--Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.0030.000173%
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 7 Pages